Erik van den Berg, AM-Pharma CEO
September 8, 2021 03:00 AM EDTUpdated 09:18 AM
Deals

Years af­ter Pfiz­er passed on a buy­out op­tion, AM-Phar­ma finds a new part­ner for its kid­ney drug

Nicole DeFeudis

Editor

A cou­ple of years ago, Pfiz­er passed on an op­tion to buy out AM-Phar­ma and its re­com­bi­nant hu­man al­ka­line phos­phatase for kid­ney fail­ure on the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Up­dat­ed: To spin off or not to spin off? Gala­pa­gos backpedals on sep­a­ra­tion plans, CEO Paul Stof­fels ex­its ear­ly

Bay­er starts 2025 by cut­ting 2,000 jobs as it homes in on year-end re­haul tar­get

Dutch biotech gets $146M for late-stage tri­als in three meta­bol­ic dis­or­ders

TIG­IT grave­yard ex­pands as GSK drops late-stage as­set with iTeos

Unit­ed­Health Group CEO An­drew Wit­ty steps down

Arc­turus to pri­or­i­tize mR­NA ther­a­peu­tics in bid to boost rare dis­ease pro­grams

A service from the Financial Times